The Long Road to Medical ‘Miracles’

Science does not often advance in sudden epiphanies that yield “Eureka” moments. More typical are years of failed experiments, dogged hypothesis-testing, and incremental discoveries that are, at best, inconclusive. And then, sometimes, eventually, the accumulated knowledge results in a breakthrough. Two recent examples are stunning advances in cancer medicine—one for pancreatic cancer, the other for melanoma—that are rewriting what doctors can promise their patients. But to understand why these achievements matter so profoundly, it is instructive to appreciate how long they took.

A Pill That Doubled Survival for the Disease That Kills Almost Everyone

Pancreatic cancer is the third-leading cause of cancer deaths in the United States, claiming nearly 53,000 lives every year. It is typically diagnosed late, treated poorly, and survived by almost no one. When doctors tell a Stage 4 pancreatic cancer patient their prognosis, they are often speaking in terms of weeks and months, not years. For decades, this grim arithmetic barely changed—not because researchers weren’t trying, but because the cancer seemed almost engineered to resist them.

The biological culprit was known. A gene called KRAS, first identified in 1982, is mutated in roughly ninety percent of pancreatic-cancer cases. When it is functioning normally, the KRAS gene produces a protein that controls cell growth, turning it on when needed and off when not. When mutated, that protein gets stuck in the “on” position, driving relentless, unchecked cell proliferation. Researchers understood this as early as the 1980s. They simply could not do anything about it.

The reason was structural. KRAS, unlike many cancer targets, presents almost no surface for a drug to grab on to. Its protein is nearly smooth—“like a golf ball with very shallow ridges,” as one researcher described it. The molecule’s fierce affinity for GTP, the cellular fuel it binds, meant that early drug candidates were simply out-competed. Despite extensive academic and industry efforts spanning four decades, KRAS resisted every therapeutic approach, earning the grim designation that haunts oncologists: “undruggable.”

The turnaround began slowly—almost invisibly—in laboratories most patients will never hear of. In 2012, two independent research groups conducting fragment-based screening found hints that KRAS was not entirely impenetrable. A small pocket had been identified near one of KRAS’s structural features, the so-called Switch II region. It was a crack in the armour. For drug developers, it was huge.

Over the following decade, chemists and biologists laboured to widen that crack into something a drug could exploit. One pioneering platform, built on complex chemistry and pursued through years of largely unglamorous bench science, eventually gave rise to a molecule at Revolution Medicines designated RMC-6236. It is now known by its clinical name, daraxonrasib.

The clinical-trial results, when they came, were startling enough to draw a standing ovation at a cancer conference from an audience of normally reserved cancer researchers. At the 2026 American Society of Clinical Oncology annual meeting in Chicago on 31 May, Dr. Brian Wolpin presented the results of an international phase 3 clinical trial involving 500 patients with metastatic pancreatic cancer who had already undergone chemotherapy. Those who received daraxonrasib lived a median of 13.2 months, compared to just 6.7 months for those receiving standard chemotherapy. Progression-free survival also doubled, from 3.6 months to 7.2 months.

“In the patient population that was being evaluated, six months is huge. It is a definite win,” said Matthew Katz, a surgical oncologist at MD Anderson Cancer Center. “The possibility is unlike, really, anything we’ve seen in pancreatic cancer in many years,” added Chris Chen of Stanford University School of Medicine.

What makes daraxonrasib particularly remarkable is its breadth of application. KRAS mutations come in multiple variants—G12D, G12V, G12R, Q61X, and others—and daraxonrasib appears to act against nearly all of them. This is enormously important. Rather than helping only patients who carry the “right” mutation, the drug may be applicable to the overwhelming majority of pancreatic cancer cases. The US Food and Drug Administration, recognising this potential, granted Breakthrough Therapy designation in June 2025 and has been actively accelerating its review.

The drug is not a cure. But for a disease that reduces hope to days and weeks, giving patients an average of six additional months—months they might spend hiking, attending a grandchild’s graduation, or simply experiencing normalcy—is a profound human achievement. And it is an achievement that was purchased over four decades with the currency of publicly funded basic science that often seemed to be disconnected from any clinical success.

The Immune Cells That Were Always There

If the pancreatic cancer story is about engineering a drug to do something the body cannot, the melanoma story is the inverse: harnessing something the body already knows how to do.